Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$12.55 - $17.22 $512,981 - $703,867
-40,875 Reduced 50.98%
39,307 $664,000
Q4 2023

Feb 06, 2024

BUY
$9.64 - $14.59 $9,341 - $14,137
969 Added 1.22%
80,182 $1.13 Million
Q3 2023

Oct 23, 2023

BUY
$10.3 - $15.99 $26,038 - $40,422
2,528 Added 3.3%
79,213 $816,000
Q2 2023

Aug 10, 2023

BUY
$8.48 - $16.48 $272,632 - $529,832
32,150 Added 72.19%
76,685 $1.26 Million
Q1 2023

May 11, 2023

BUY
$6.41 - $9.95 $25,024 - $38,844
3,904 Added 9.61%
44,535 $407,000
Q4 2022

Feb 07, 2023

BUY
$5.02 - $10.0 $39,868 - $79,420
7,942 Added 24.3%
40,631 $290,000
Q3 2022

Nov 14, 2022

BUY
$2.57 - $7.31 $43,690 - $124,270
17,000 Added 108.36%
32,689 $163,000
Q2 2022

Jul 19, 2022

SELL
$1.07 - $6.95 $478 - $3,106
-447 Reduced 2.77%
15,689 $38,000
Q1 2022

May 04, 2022

BUY
$5.46 - $8.29 $5,460 - $8,290
1,000 Added 6.61%
16,136 $110,000
Q4 2021

Jan 31, 2022

SELL
$7.34 - $11.18 $11,898 - $18,122
-1,621 Reduced 9.67%
15,136 $122,000
Q3 2021

Oct 29, 2021

SELL
$6.49 - $9.91 $13,758 - $21,009
-2,120 Reduced 11.23%
16,757 $164,000
Q2 2021

Aug 11, 2021

SELL
$6.73 - $9.05 $11,441 - $15,385
-1,700 Reduced 8.26%
18,877 $127,000
Q1 2021

May 04, 2021

BUY
$6.61 - $10.07 $43,956 - $66,965
6,650 Added 47.75%
20,577 $186,000
Q4 2020

Feb 11, 2021

SELL
$5.03 - $7.95 $4,275 - $6,757
-850 Reduced 5.75%
13,927 $93,000
Q3 2020

Nov 05, 2020

BUY
$5.02 - $8.98 $2,685 - $4,804
535 Added 3.76%
14,777 $74,000
Q2 2020

Aug 12, 2020

BUY
$7.25 - $11.75 $103,254 - $167,343
14,242 New
14,242 $115,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $661M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.